ANP Peptide Species Variants: Human, Rat and Mouse Sequences Are Not Interchangeable

The mature 28-residue peptides of human, rat and mouse are highly similar. The substitution I have verified most often is at position twelve of the mature peptide, where human ANP carries methionine and rat ANP carries isoleucine. Mouse records I have checked usually show the same isoleucine as rat at that position.

Divergence is larger outside the mature peptide. The prohormone region differs more between species than the mature form does, so a paper working on precursor fragments needs a tighter species statement than one working on the mature peptide. I check the prohormone separately every time.

I state these as recorded rather than settled, because sequence records are revised. Every entry in this section carries the date I checked it and the record I checked it against, and any anp peptide species variants claim in my notes without those two fields is held as provisional.

Position twelve lies in the N-terminal segment, outside the 17-residue disulfide ring. That placement matters: the ring is the conserved core required for receptor activation, so the species change falls in a region that contributes less to activation and more to recognition by antibodies and to processing.

The practical consequence is that functional comparisons often survive a species substitution better than measurement comparisons do. A potency ratio measured in one species may transfer roughly, while an absolute concentration read by an immunoassay built on the human sequence may not transfer at all.

That asymmetry is the whole argument for recording species explicitly. A reader who sees only the peptide name cannot tell which kind of comparison they are looking at, and anp peptide species variants errors tend to enter the record exactly at that point, where a qualifier was dropped to shorten a sentence.

Most immunoassays for this family are raised and characterised against one sequence, usually human. Cross-reactivity with the rat or mouse peptide is then an empirical property of that reagent, and the stated values in my notes vary widely between reagents nominally reading the same analyte.

This is the mechanism behind many of the disagreements I have logged between studies. Two groups measure the same analyte in the same tissue, one uses a reagent validated on human sequence and the other on rodent sequence, and the resulting numbers differ for reasons that have nothing to do with the biology.

When I compare two studies I therefore read the reagent section before the results. If the two papers used reagents with different stated cross-reactivity, I record their values as non-comparable rather than averaging them, which is the habit that removed most of the contradictions from my early notes. See my ANP research notes.

Potency is a property of a pair, not of a peptide alone. The receptor also varies by species, so comparing human ANP at human NPR-A with rat ANP at rat NPR-A is a different experiment from mixing the two. Papers that mix them are not wrong, but they answer a different question than the one a reader usually assumes.

I therefore file potency entries with four fields: peptide species, receptor species, expression system and readout. Where a paper omits one, the entry is marked partial. See the ANP notes I maintain.

Mixed pairs are not useless, only narrower. A human peptide tested at a rodent receptor answers a question about that pairing, and it is a reasonable design when the goal is to characterise a reagent rather than a physiology. The mistake is reading the result as if both sides came from one species.

Misquotation is common enough that I now assume it until checked. A review quotes a value from a rat study, the next review drops the species because the sentence reads cleanly without it, and within a few years the value circulates as if it came from human work. Tracing those chains is slow but it is the only way I have found to keep anp peptide species variants claims honest.

I also watch the figures themselves. Sequence alignments reprinted in reviews sometimes carry a residue from the wrong row, and a misprinted alignment is copied as reliably as a correct one. Any alignment I reuse gets rebuilt from the primary records before it goes into my notes.

A usable methods section names the species of the peptide, gives the sequence or an unambiguous fragment boundary, states whether the material is the mature form or a prohormone-derived fragment, and identifies the source. Those four items are what let a later reader rebuild the experiment.

Verification is then mechanical. I take the stated sequence to a public protein database record for the gene in that species and compare residue by residue, including the position I expect to differ. If the paper sequence and the record disagree, I keep both and flag the entry. See editorial notes.

The last check is provenance. A sequence that appears only in a review and never in a primary methods section is stored as unverified, no matter how many later papers repeat it. Repetition is not verification, and the anp peptide species variants literature has enough repeated errors to make that distinction worth keeping.